Atish Choudhury, MD PhD
@AtishChoudhury
Followers
1K
Following
1K
Statuses
316
Medical Oncologist Lank Center for Genitourinary Oncology @DanaFarber Views expressed herein are my own
Boston, MA
Joined September 2016
Thank you @DanaFarber for this recognition, and to @DrChoueiri for your guidance and advocacy. I appreciate all the support from mentors, collaborators, colleagues, research staff, and trial participants as we try to continue to advance care of patients with GU cancers.
Congratulations to @DanaFarber_GU Dr. @AtishChoudhury for his prestigious George Canellos Excellence in Clinical Investigation @DanaFarber !! @DanaFarberNews @harvardmed
8
3
71
Now activated! CLEARED will enroll pts with high-risk localized, lymph node-positive or low volume HSPC (planned for treatment interruption) to receive 2 years of relugolix+darolutamide for PK studies of the combo and to assess T recovery after completion.
Thank you to @NCCN, @SumitomoPharma, @PfizerOncMed, @BayerOncMed for supporting our study entitled Comeback from Long CoursE ADT with RElugolix and Darolutamide (CLEARED), testing T recovery (and exploring QOL and PK) with 2 years of this combination in HSPC. @DanaFarber_GU
1
2
10
It's not too late to join our contribute to our team at to support Movember's efforts towards prostate cancer, testicular cancer and mental health research and resources.
0
1
2
@ProtonStorey @PrafulRavi1 @EurUrolOncol Thank you for your comments. What we discuss is that SBRT with short course ADT may prolong time to next ADT cycle, but what we are seeing in a subset of patients treated with prolonged ADT is T recovery without need for ANY further treatment for as long as we have been following
0
0
1
On multivariable analysis, duration of treatment >=12 months was independently associated with cPFS after T recovery, provocatively suggesting that prolonged systemic therapy could sterilize (or render permanently dormant) micrometastatic disease and lead to "cure" in a subset.
0
0
2
RT @PrafulRavi1: Can oligometastatic prostate cancer be cured with ‘total therapy’? Check out our paper reporting on outcomes after fixed-d…
0
22
0
RT @AarmstrongDuke: Great job @DRathkopf @myESMO presenting on our new AR degrader! Now published in @Annals_Oncology for more details: htt…
0
11
0
I am so appreciative that my dear patient Adam was willing to come out to Fenway Park for the @WEEI / @NESN @TheJimmyFund Radio-Telethon on his wedding anniversary (!) to raise awareness around testicular cancer and to support research at @DanaFarber @DanaFarber_GU. #KCANCER
Jones & Mego: Adam Reczkowski, 41, testicular cancer, Dedham, and Atish Choudhury, MD, PhD, Clinical Investigator in the Lank Center for Genitourinary Oncology, and Chair of the Gelb Center for Translational Research, Instructor in Medicine, Dana-Farber
1
1
16
Successfully matching blood and tissue samples from clinical trials labeled with a 16 character biospecimen ID, to study participants identified by a 10 character trial ID.
0
0
4
RT @CIR_AACR: New from the June issue— Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in #Metastatic Cast…
0
1
0
Awesome to see you, @JessicaHawleyMD, and congratulations on your trial - looking forward to seeing the results!
0
0
8
Thank you for this write-up, @RKSayyid @urotoday! We have completed enrollment, and are eager to follow outcomes in terms of time off treatment and quality of life. Many thanks to the co-investigators and to the patients who enrolled.
#ASCO24 TiP A-DREAM/Alliance A032101: Ph 2 trial of systemic therapy de-intensification for mHSPC pts w/ excellent response to ARPI + ADT (PSA <0.2 after 18-24 mo ADT & ≥12 mo ARPI both d/c) 🔹PSA/T q 3 mo, scans q 3-6 mo 🔹Re-initiation triggers: PSA≥5, radiographic change, PCa symptoms 🔹Primary endpoint: 18-mo eugonadal treatment-free survival 📍78 pts recruited to date. F/u pending @urotoday @AtishChoudhury
0
2
8
QOL advantage would probably be modest in most patients since T recovery will be infrequent as noted by @BertrandTOMBAL. Rising PSA may need to be allowed to define "progression" here and not have to wait until confirmed progression by PCWG3 for patient/provider comfort.
0
0
3
@bergsa83 - it's wonderful to read about how you came to join #TeamBellissimo in support of @Movember and inspire others to do the same! @RickLee6 @DrPaulNguyen @loreleimucci @DrPhilKantoff @MA_Preston @LaurenCHarshman @BWHUrology @BrighamRadOnc @adamkibel_uro @mishabeltran
@MovemberUSA Thank you for featuring below: It’s time to take back your health , loved working with the team! @DanaFarber_GU @DanaFarberNews @DrChoueiri @AtishChoudhury @ASCO
0
0
3
RT @bergsa83: My patient sent me this today! I’m so grateful. 👏🏼Cheers to our patients and our MA state legislature #testicularcancer @Chr…
0
7
0